Novel Biomarkers Predict the Development of Incident Heart Failure
By LabMedica International staff writers Posted on 30 Dec 2020 |

Image: The IMMAGE 800 protein chemistry analyzer (Photo courtesy of Beckman Coulter).
Heart failure (HF), caused by abnormal cardiac structure and function, represents the end stage of several cardiac diseases, and significantly worsens both quality of life and life expectancy with a five year survival rate of approximately 50%. Lifetime risk of the development of HF is 20% and overall prevalence 2%.
Natriuretic peptides and troponins have been used in clinical diagnosis and treatment of HF, and they also predict incident HF. Transition from current practice of treating HF to biomarker‐based precise medicine targeted to prevent HF requires investigation of multiple biomarkers reflective of pathophysiological pathways resulting in HF.
Clinical Medical Scientists from the University of Eastern Finland (Kuopio, Finland) and the Kuopio University Hospital (Kuopio, Finland) used a random selection of 10,106 men, aged from 45 to 73 years, participating in the Metabolic Syndrome in Men (METSIM) study, who at baseline did not have a diagnosis of incident heart failure. Blood samples for proton nuclear magnetic resonance (NMR) analysis, metabolic, inflammatory, and other biomarkers were taken.
Levels of plasma glucose, insulin, hemoglobin A1c (HbA1c), glomerular filtration rate and urinary albumin excretions rate were measured and a two hour oral glucose tolerance test (75 g of glucose) was performed. Serum concentrations of hs‐CRP were assayed using kinetic immunoturbidimetry (IMMAGE Immunochemistry System; Beckman Coulter, Fullerton, CA, USA) and plasma interleukin 1 receptor antagonist (IL‐1RA) using an enzyme‐linked immunosorbent assay (ELISA) (R&D Systems, Inc., Minneapolis, MN, USA). Plasma adiponectin was measured using an ELISA kit (Linco Research, St. Charles, MI, USA). Proton nuclear magnetic resonance analysis was performed at the same time from the baseline serum samples.
The scientists reported that elevated levels of inflammatory biomarkers and several biomarkers associated with heart metabolism, which were measured by NMR analysis, were associated with the development of incident heart failure in a follow-up that lasted for 8.8 years. These new biomarkers included adiponectin, high-sensitivity C-reactive protein, the chronic inflammation biomarker glycoprotein acetyls, the amino acids alanine and phenylalanine, as well as glycerol and pyruvate, which the heart muscle uses for energy. Fasting plasma glucose and insulin, HbA1c, and urinary albumin excretion rate were also associated with HF.
Johanna Kuusisto, MD a Professor of Cardiology and senior author of the study, said, “Incident heart failure is typically associated with changes in heart metabolism as well as with low-grade, chronic inflammation. Based on our study, these changes are present even years before any sign of heart failure.” The study was published on December 5, 2020 in the journal ESC Heart Failure.
Related Links:
University of Eastern Finland
Kuopio University Hospital
Beckman Coulter
R&D Systems
Linco Research
Natriuretic peptides and troponins have been used in clinical diagnosis and treatment of HF, and they also predict incident HF. Transition from current practice of treating HF to biomarker‐based precise medicine targeted to prevent HF requires investigation of multiple biomarkers reflective of pathophysiological pathways resulting in HF.
Clinical Medical Scientists from the University of Eastern Finland (Kuopio, Finland) and the Kuopio University Hospital (Kuopio, Finland) used a random selection of 10,106 men, aged from 45 to 73 years, participating in the Metabolic Syndrome in Men (METSIM) study, who at baseline did not have a diagnosis of incident heart failure. Blood samples for proton nuclear magnetic resonance (NMR) analysis, metabolic, inflammatory, and other biomarkers were taken.
Levels of plasma glucose, insulin, hemoglobin A1c (HbA1c), glomerular filtration rate and urinary albumin excretions rate were measured and a two hour oral glucose tolerance test (75 g of glucose) was performed. Serum concentrations of hs‐CRP were assayed using kinetic immunoturbidimetry (IMMAGE Immunochemistry System; Beckman Coulter, Fullerton, CA, USA) and plasma interleukin 1 receptor antagonist (IL‐1RA) using an enzyme‐linked immunosorbent assay (ELISA) (R&D Systems, Inc., Minneapolis, MN, USA). Plasma adiponectin was measured using an ELISA kit (Linco Research, St. Charles, MI, USA). Proton nuclear magnetic resonance analysis was performed at the same time from the baseline serum samples.
The scientists reported that elevated levels of inflammatory biomarkers and several biomarkers associated with heart metabolism, which were measured by NMR analysis, were associated with the development of incident heart failure in a follow-up that lasted for 8.8 years. These new biomarkers included adiponectin, high-sensitivity C-reactive protein, the chronic inflammation biomarker glycoprotein acetyls, the amino acids alanine and phenylalanine, as well as glycerol and pyruvate, which the heart muscle uses for energy. Fasting plasma glucose and insulin, HbA1c, and urinary albumin excretion rate were also associated with HF.
Johanna Kuusisto, MD a Professor of Cardiology and senior author of the study, said, “Incident heart failure is typically associated with changes in heart metabolism as well as with low-grade, chronic inflammation. Based on our study, these changes are present even years before any sign of heart failure.” The study was published on December 5, 2020 in the journal ESC Heart Failure.
Related Links:
University of Eastern Finland
Kuopio University Hospital
Beckman Coulter
R&D Systems
Linco Research
Latest Clinical Chem. News
- ‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
- Low-Cost Portable Screening Test to Transform Kidney Disease Detection
- New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
- Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
- Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
- AI-Powered Raman Spectroscopy Method Enables Rapid Drug Detection in Blood
- Novel LC-MS/MS Assay Detects Low Creatinine in Sweat and Saliva
- Biosensing Technology Breakthrough Paves Way for New Methods of Early Disease Detection
- New Saliva Test Rapidly Identifies Paracetamol Overdose
- POC Saliva Testing Device Predicts Heart Failure in 15 Minutes
- Screening Tool Detects Multiple Health Conditions from Single Blood Drop
- Integrated Chemistry and Immunoassay Analyzer with Extensive Assay Menu Offers Flexibility, Scalability and Data Commutability
- Rapid Drug Test to Improve Treatment for Patients Presenting to Hospital
- AI Model Detects Cancer at Lightning Speed through Sugar Analyses
- First-Ever Blood-Powered Chip Offers Real-Time Health Monitoring
- New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections
Channels
Molecular Diagnostics
view channel
Simple Blood Test Improves Heart Attack and Stroke Risk Prediction
Troponin is a protein found in heart muscle cells that is released into the bloodstream when the heart is damaged. High-sensitivity troponin blood tests are commonly used in hospitals to diagnose heart... Read more
Blood Biomarker Test Could Detect Genetic Predisposition to Alzheimer’s
New medications for Alzheimer’s disease, the most common form of dementia, are now becoming available. These treatments, known as “amyloid antibodies,” work by promoting the removal of small deposits from... Read more
Novel Autoantibody Against DAGLA Discovered in Cerebellitis
Autoimmune cerebellar ataxias are strongly disabling disorders characterized by an impaired ability to coordinate muscle movement. Cerebellar autoantibodies serve as useful biomarkers to support rapid... Read more
Gene-Based Blood Test Accurately Predicts Tumor Recurrence of Advanced Skin Cancer
Melanoma, an aggressive form of skin cancer, becomes extremely difficult to treat once it spreads to other parts of the body. For patients with metastatic melanoma tumors that cannot be surgically removed... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
Spit Test More Accurate at Identifying Future Prostate Cancer Risk
Currently, blood tests that measure the level of a protein called prostate-specific antigen (PSA) are commonly used to identify men at higher risk for prostate cancer. This test is typically used based... Read more
DNA Nanotechnology Boosts Sensitivity of Test Strips
Since the Covid-19 pandemic, most people have become familiar with paper-based rapid test strips, also known as lateral flow immunoassays (LFIAs). These tests are used to quickly detect biomarkers that... Read more
Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures
Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read moreTechnology
view channel
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more